BACKGROUND: No longitudinal study has yet examined the association between substance use and brain volume changes in a population at high risk of schizophrenia. AIMS: To examine the effects of cannabis on longitudinal thalamus and amygdala-hippocampal complex volumes within a population at high risk of schizophrenia. METHOD: Magnetic resonance imaging scans were obtained from individuals at high genetic risk of schizophrenia at the point of entry to the Edinburgh High-Risk Study (EHRS) and approximately 2 years later. Differential thalamic and amygdala-hippocampal complex volume change in high-risk individuals exposed (n = 25) and not exposed (n = 32) to cannabis in the intervening period was investigated using repeated-measures analysis of variance. RESULTS: Cannabis exposure was associated with bilateral thalamic volume loss. This effect was significant on the left (F = 4.47, P = 0.04) and highly significant on the right (F= 7.66, P= 0.008). These results remained significant when individuals using other illicit drugs were removed from the analysis. CONCLUSIONS: These are the first longitudinal data to demonstrate an association between thalamic volume loss and exposure to cannabis in currently unaffected people at familial high risk of developing schizophrenia. This observation may be important in understanding the link between cannabis exposure and the subsequent development of schizophrenia.
BACKGROUND: No longitudinal study has yet examined the association between substance use and brain volume changes in a population at high risk of schizophrenia. AIMS: To examine the effects of cannabis on longitudinal thalamus and amygdala-hippocampal complex volumes within a population at high risk of schizophrenia. METHOD: Magnetic resonance imaging scans were obtained from individuals at high genetic risk of schizophrenia at the point of entry to the Edinburgh High-Risk Study (EHRS) and approximately 2 years later. Differential thalamic and amygdala-hippocampal complex volume change in high-risk individuals exposed (n = 25) and not exposed (n = 32) to cannabis in the intervening period was investigated using repeated-measures analysis of variance. RESULTS: Cannabis exposure was associated with bilateral thalamic volume loss. This effect was significant on the left (F = 4.47, P = 0.04) and highly significant on the right (F= 7.66, P= 0.008). These results remained significant when individuals using other illicit drugs were removed from the analysis. CONCLUSIONS: These are the first longitudinal data to demonstrate an association between thalamic volume loss and exposure to cannabis in currently unaffected people at familial high risk of developing schizophrenia. This observation may be important in understanding the link between cannabis exposure and the subsequent development of schizophrenia.
Authors: Paul Klauser; Juan Zhou; Joseph K W Lim; Joann S Poh; Hui Zheng; Han Ying Tng; Ranga Krishnan; Jimmy Lee; Richard S E Keefe; R Alison Adcock; Stephen J Wood; Alex Fornito; Michael W L Chee Journal: Schizophr Bull Date: 2015-03-04 Impact factor: 9.306
Authors: Matthew J Smith; Derin J Cobia; Lei Wang; Kathryn I Alpert; Will J Cronenwett; Morris B Goldman; Daniel Mamah; Deanna M Barch; Hans C Breiter; John G Csernansky Journal: Schizophr Bull Date: 2013-12-15 Impact factor: 9.306
Authors: Lisa Buchy; Daniel H Mathalon; Tyrone D Cannon; Kristin S Cadenhead; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Jean Addington Journal: Psychiatry Res Neuroimaging Date: 2016-06-02 Impact factor: 2.376
Authors: Nathan A Gillespie; Michael C Neale; Timothy C Bates; Lisa T Eyler; Christine Fennema-Notestine; Jasmin Vassileva; Michael J Lyons; Elizabeth C Prom-Wormley; Katie L McMahon; Paul M Thompson; Greig de Zubicaray; Ian B Hickie; John J McGrath; Lachlan T Strike; Miguel E Rentería; Matthew S Panizzon; Nicholas G Martin; Carol E Franz; William S Kremen; Margaret J Wright Journal: Addiction Date: 2018-04-24 Impact factor: 6.526
Authors: Berend Malchow; Alkomiet Hasan; Thomas Schneider-Axmann; Alexander Jatzko; Oliver Gruber; Andrea Schmitt; Peter Falkai; Thomas Wobrock Journal: Eur Arch Psychiatry Clin Neurosci Date: 2013-10-02 Impact factor: 5.270
Authors: Albert Batalla; Sagnik Bhattacharyya; Murat Yücel; Paolo Fusar-Poli; Jose Alexandre Crippa; Santiago Nogué; Marta Torrens; Jesús Pujol; Magí Farré; Rocio Martin-Santos Journal: PLoS One Date: 2013-02-04 Impact factor: 3.240